Identification and Validation of Inverse Agonists for Nuclear Receptor Subfamily 4 Group A Member 2.

Former studies indicate that nuclear receptor subfamily 4 group A member 2 (Nurr1, NR4A2), a transcription factor, is regarded as a potential therapeutic target for central nervous system diseases, and many studies have focused on the development and optimization of agonists of Nurr1. Recent studies have shown that Nurr1 is upregulated in many other diseases. However, there is still a lack of effective inverse Nurr1 agonists as a therapeutic strategy or as pharmacological tools to counteract the receptor's inherent activity. In this study, we screened Nurr1 ligands through a high-throughput screening system and identified a novel Nurr1 inverse agonist (K-strophanthoside). We further validated the binding site of K-strophanthoside on Nurr1 and investigated its effect on regulating Nurr1 function. K-strophanthoside directly binds to the ligand-binding domain of Nurr1 (Glu445, Glu514, Arg515, and His516) and mimics the function of Nurr1 knockdown by suppressing the intrinsic Nurr1 transcriptional activity. Our study contributes a valuable chemical tool for Nurr1 modulators and provides a potential treatment target for Nurr1-related disorders.